LSB Key Statistics, Chart & Performance
The current stock price of LSB is 0.627 USD. In the past month the price decreased by -25%. In the past year, price decreased by -18.57%.
LSB Latest News, Press Relases and Analysis
LSB Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.63 | 394.69B | ||
| AMGN | AMGEN INC | 14.53 | 171.10B | ||
| GILD | GILEAD SCIENCES INC | 14.7 | 149.38B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.04 | 114.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.47 | 77.91B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 779.51 | 52.52B | ||
| INSM | INSMED INC | N/A | 42.02B | ||
| NTRA | NATERA INC | N/A | 32.01B | ||
| BIIB | BIOGEN INC | 10.4 | 25.54B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.72 | 21.27B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.26B | ||
| INCY | INCYTE CORP | 14.86 | 18.73B |
Related stock screener links
About LSB
Company Profile
LakeShore Biopharma Co., Ltd. engages in the provision of discovering, developing, manufacturing, and commercializing vaccines and therapeutic biologics for infectious diseases and cancer. The company is headquartered in Beijing, Beijing and currently employs 573 full-time employees. The company went IPO on 2021-07-30. The firm's vaccine product YSJATM rabies vaccine has been commercialized. The firm also has four product candidates under various clinical development stages, including PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, PIKA YS-ON-001 and PIKA YS-HBV-001, and four preclinical stage product candidates, targeting HBV, influenza and cancer with enormous medical demand. In addition, the Company is working on a series of therapeutic targets, rabies and products at the discovery stage.
Company Info
LAKESHORE BIOPHARMA CO LTD
Building No. 2, 38 Yongda Road, Daxing Biomedical Industry Park, Daxing District
Beijing BEIJING CN
Employees: 573
Phone: 17327133678
LAKESHORE BIOPHARMA CO LTD / LSB FAQ
Can you describe the business of LAKESHORE BIOPHARMA CO LTD?
LakeShore Biopharma Co., Ltd. engages in the provision of discovering, developing, manufacturing, and commercializing vaccines and therapeutic biologics for infectious diseases and cancer. The company is headquartered in Beijing, Beijing and currently employs 573 full-time employees. The company went IPO on 2021-07-30. The firm's vaccine product YSJATM rabies vaccine has been commercialized. The firm also has four product candidates under various clinical development stages, including PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, PIKA YS-ON-001 and PIKA YS-HBV-001, and four preclinical stage product candidates, targeting HBV, influenza and cancer with enormous medical demand. In addition, the Company is working on a series of therapeutic targets, rabies and products at the discovery stage.
What is the stock price of LAKESHORE BIOPHARMA CO LTD today?
The current stock price of LSB is 0.627 USD. The price decreased by -20.68% in the last trading session.
What is the dividend status of LAKESHORE BIOPHARMA CO LTD?
LSB does not pay a dividend.
How is the ChartMill rating for LAKESHORE BIOPHARMA CO LTD?
LSB has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What do analysts say about LAKESHORE BIOPHARMA CO LTD (LSB) stock?
5 analysts have analysed LSB and the average price target is 31.62 USD. This implies a price increase of 4943.06% is expected in the next year compared to the current price of 0.627.
What sector and industry does LAKESHORE BIOPHARMA CO LTD belong to?
LAKESHORE BIOPHARMA CO LTD (LSB) operates in the Health Care sector and the Biotechnology industry.
Would investing in LAKESHORE BIOPHARMA CO LTD be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on LSB.
LSB Technical Analysis
LSB Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to LSB. LSB may be in some trouble as it scores bad on both profitability and health.
LSB Financial Highlights
Over the last trailing twelve months LSB reported a non-GAAP Earnings per Share(EPS) of -0.73. The EPS increased by 87.13% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -7.31% | ||
| ROE | -20.01% | ||
| Debt/Equity | 0.05 |
LSB Forecast & Estimates
5 analysts have analysed LSB and the average price target is 31.62 USD. This implies a price increase of 4943.06% is expected in the next year compared to the current price of 0.627.
For the next year, analysts expect an EPS growth of 105.67% and a revenue growth 75.61% for LSB